Astonea Labs share price, P/E, ROE & financials

As of 4 Nov 2026, Astonea Labs trades at 74.6× trailing earnings, above the industry P/E of 28.7×. Its ROCE of 11% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 31% and 89% a year over 3 years. Debt is 0.75× equity. It is listed on an SME platform with a market cap of ₹352 Cr, ranked 85th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 115% over the past year.

As of 4 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Mar 2026.How we calculate this

past year

Open: ₹335.00
Day high: ₹335.00
Day low: ₹335.00
Prev. close: ₹335.00
Volume: 1K

Health check

2 good · 1 fair · 3 to check

ReturnsAhead
+114.7% over a year, better than 6 of 7 peers.
Price tagPricier
P/E 74.6 vs industry 28.7.
GrowthStrong
Sales +30.7%, profit +89.3% a year over 3 years.
ProfitabilityWeak
ROCE 11.4% vs peer median 17.9%.
Balance sheetFair
Debt 0.75× equity, interest covered 2.7×, Piotroski 6 of 9.
Red flags1 to check
P/E of 74.6 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹352 Cr, #85 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Mar 2026: sales ₹148 Cr · profit ₹5 Cr

Market cap: ₹352 Cr; Small cap
P/E: 74.6; Industry 28.7
Price to book: 6.16; Peers 4.99
Dividend yield: 0.00%
ROE: 12.0%; Peers 14.7%
ROCE: 11.4%; Peers 17.9%
Debt to equity: 0.75; Debt ₹43 Cr
EPS (TTM): ₹4.49
OPM (TTM): 6.9%; Net margin 3.1%
Sales growth: +191.1%; Latest quarter vs a year ago
Profit growth: +148.3%; Latest quarter vs a year ago
Price to sales: 2.39; EV/EBITDA 28.5

Strengths

Quarterly profit up 148.3% on a year ago.
Quarterly sales up 191.1% on a year ago.

Risks to check

P/E of 74.6 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Astonea Labs

Astonea Labs Limited manufactures and markets pharmaceutical and cosmetic products under the Glow Up, Avicel, and Regero brand names in India and internationally. The company offers pharmaceutical products, including generics, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as cosmetic and personal care products, such as skincare, haircare, anti-aging, ethical, and organic cosmetic lines. It offers its products in tablets,…

Headquarters: Panchkula
Sector: Healthcare
ISIN: INE0TG901011
Website: astonea.org

Price range

52 weeks

₹118.00₹369.00

Today

₹335.00₹335.00

Avg volume (3M): 3.3K
1-year return: plus 114.7%
From 52-week high: minus 9.2%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
ASTONEALABAstonea Labs	335.00	0.00%	352	74.6	6.16	11.4%	12.0%	6.9%	30.7%	89.3%	0.00%	plus 114.7%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore · latest reported Mar 26

SalesSelect a row below to chart it

₹ Cr	Mar 25	Mar 26
	27.9	81.3
	24.1	73.3
	3.8	8
	13.5%	9.8%
	−0.1	0.4
	0.9	1.7
	1.1	2.8
	1.7	3.8
	26.8%	19.5%
	1.2	3.1
	–	3.08

Jun 25, Sep 25, Dec 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +30.7%
Profit CAGR 3Y: +89.3%
ROE: 12.0%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
66.1	79.3	97.2	148
–	+20.0%	+22.5%	+51.8%
59	67.2	82.1	134
7.1	12.1	15.1	13.5
10.8%	15.3%	15.5%	9.2%
−0	−0.1	0.1	0.4
2.3	2.7	3.5	3.3
3.9	3.7	4.6	5
0.2	−0.2	−0	–
1.1	5.4	7.1	5.6
38.5%	24.3%	24.3%	19.7%
0.7	4.1	5.4	4.5
–	+511.9%	+31.5%	minus 15.6%
0.63	3.87	5.09	–

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4	7.6	7.7	10.5
4.2	4.4	10.7	46.6
36	42.4	53.3	43
20.1	26.5	31.6	46.1
64.3	80.9	103	146
20.7	24	29.8	38.7
–	2.1	4.4	7.7
0.9	1.8	2.2	2
0	0.3	0.1	0.2
42.6	52.7	66.9	97.7
64.3	80.9	103	146

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−1.1	7.9	9.2	−13.6
−3.1	−8.3	−11.1	−19.9
4.1	−0.3	1.6	33.6
0	−0.8	−0.3	0.1
−3.1	−7.5	−10.8	−14
−4.2	0.4	−1.5	−27.6

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you